{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:37:13Z","timestamp":1792496233471,"version":"4.5.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2816\/1"],"award-info":[{"award-number":["GRK 2816\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1123"],"award-info":[{"award-number":["SFB1123"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR152"],"award-info":[{"award-number":["TRR152"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TRR296"],"award-info":[{"award-number":["TRR296"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF21OC0072718"],"award-info":[{"award-number":["NNF21OC0072718"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","award":["NNF21SA0072746"],"award-info":[{"award-number":["NNF21SA0072746"]}],"id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["101044445"],"award-info":[{"award-number":["101044445"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010215","name":"Deutsche Diabetes Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010215","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["1052-00003B"],"award-info":[{"award-number":["1052-00003B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["R01DK132669"],"award-info":[{"award-number":["R01DK132669"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00125-023-05947-y","type":"journal-article","created":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T04:03:36Z","timestamp":1687838616000},"page":"1378-1394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["100 years of glucagon and 100 more"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-5753","authenticated-orcid":false,"given":"Nicolai J.","family":"Wewer Albrechtsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J.","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Cherrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Finan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte","family":"Gluud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Danielle","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia M.-M.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-5034","authenticated-orcid":false,"given":"Filip K.","family":"Knop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo D.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,27]]},"reference":[{"issue":"3","key":"5947_CR1","first-page":"141","volume":"12","author":"FG Banting","year":"1922","unstructured":"Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA (1922) Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 12(3):141\u2013146","journal-title":"Can Med Assoc J"},{"key":"5947_CR2","unstructured":"Collip JB (1923) Delayed manifestation of the physiological effects of insulin following the administration of certain pancreatic extracts. Am J Physiol 63:February"},{"issue":"1","key":"5947_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1152\/ajplegacy.1923.67.1.57","volume":"67","author":"NF Fisher","year":"1923","unstructured":"Fisher NF (1923) I. Preparation of insulin. Am J Physiol Legacy Content 67(1):57\u201364. https:\/\/doi.org\/10.1152\/ajplegacy.1923.67.1.57","journal-title":"Am J Physiol Legacy Content"},{"issue":"1","key":"5947_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0021-9258(18)85474-6","volume":"58","author":"CP Kimball","year":"1923","unstructured":"Kimball CP, Murlin JR (1923) Aqueous extracts of pancreas: III. Some precipitation reactions of insulin. J Biol Chem 58(1):337\u2013346. https:\/\/doi.org\/10.1016\/S0021-9258(18)85474-6","journal-title":"J Biol Chem"},{"key":"5947_CR5","doi-asserted-by":"publisher","unstructured":"Sutherland E (1950) The effect of the hyperglycemic factor in the pancreas and of epinephrine on glycogenolysis. Recent Prog Horm Res 172(737). https:\/\/doi.org\/10.1016\/B978-0-12-571105-0.50016-2","DOI":"10.1016\/B978-0-12-571105-0.50016-2"},{"issue":"3049","key":"5947_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1126\/science.117.3049.628","volume":"117","author":"A Staub","year":"1953","unstructured":"Staub A, Sinn L, Behrens OK (1953) Purification and crystallization of hyperglycemic glycogenolytic factor (HGF). Science 117(3049):628\u2013629. https:\/\/doi.org\/10.1126\/science.117.3049.628","journal-title":"Science"},{"issue":"3","key":"5947_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2337\/diab.6.3.234","volume":"6","author":"WW Bromer","year":"1957","unstructured":"Bromer WW, Sinn LG, Staub A, Behrens OK (1957) The amino acid sequence of glucagon. Diabetes 6(3):234\u2013238. https:\/\/doi.org\/10.2337\/diab.6.3.234","journal-title":"Diabetes"},{"issue":"2","key":"5947_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0021-9258(18)56702-8","volume":"180","author":"EW Sutherland","year":"1949","unstructured":"Sutherland EW, Cori CF, Haynes R, Olsen N et al (1949) Purification of the hyperglycemic-glycogenolytic factor from insulin and from gastric mucosa. J Biol Chem 180(2):825\u2013837. https:\/\/doi.org\/10.1016\/S0021-9258(18)56702-8","journal-title":"J Biol Chem"},{"key":"5947_CR9","doi-asserted-by":"publisher","unstructured":"Vuylsteke CA, Cornelis G, de Duve C (1952) Influence du traitement au cobalt sur le contenu en facteur H-G du pancreas de Cobaye. Arch Int Physiol 60(1):128\u2013131. https:\/\/doi.org\/10.3109\/13813455209145047. ([article in French])","DOI":"10.3109\/13813455209145047"},{"key":"5947_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3181\/00379727-102-25338","volume":"102","author":"RH Unger","year":"1959","unstructured":"Unger RH, Eisentraut AM, McCall MS, Keller S, Lanz HC, Madison LL (1959) Glucagon antibodies and their use for immunoassay for glucagon. Proc Soc Exp Biol Med 102:621\u2013623. https:\/\/doi.org\/10.3181\/00379727-102-25338","journal-title":"Proc Soc Exp Biol Med"},{"issue":"9","key":"5947_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJM197808312990901","volume":"299","author":"P Raskin","year":"1978","unstructured":"Raskin P, Unger RH (1978) Hyperglucagonemia and its suppression. N Engl J Med 299(9):433\u2013436. https:\/\/doi.org\/10.1056\/NEJM197808312990901","journal-title":"N Engl J Med"},{"issue":"4","key":"5947_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1172\/JCI106297","volume":"49","author":"RH Unger","year":"1970","unstructured":"Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49(4):837\u2013848. https:\/\/doi.org\/10.1172\/JCI106297","journal-title":"J Clin Invest"},{"issue":"1","key":"5947_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1172\/JCI60016","volume":"122","author":"RH Unger","year":"2012","unstructured":"Unger RH, Cherrington AD (2012) Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122(1):4\u201312. https:\/\/doi.org\/10.1172\/JCI60016","journal-title":"J Clin Invest"},{"key":"5947_CR14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0021-9258(18)57183-0","volume":"175","author":"EW Sutherland","year":"1948","unstructured":"Sutherland EW, de Duve C (1948) Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. J Biol Chem 175:663\u2013674. https:\/\/doi.org\/10.1016\/S0021-9258(18)57183-0","journal-title":"J Biol Chem"},{"issue":"21","key":"5947_CR15","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.3390\/ijms20215416","volume":"20","author":"JJ Holst","year":"2019","unstructured":"Holst JJ, WewerAlbrechtsen NJ (2019) Methods and guidelines for measurement of glucagon in plasma. Int J Mol Sci 20(21):5416. https:\/\/doi.org\/10.3390\/ijms20215416","journal-title":"Int J Mol Sci"},{"issue":"8","key":"5947_CR16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/0026-0495(73)90215-1","volume":"22","author":"RH Unger","year":"1973","unstructured":"Unger RH (1973) Radioimmunoassay of glucagon. Metab Clin Exp 22(8):979\u2013985. https:\/\/doi.org\/10.1016\/0026-0495(73)90215-1","journal-title":"Metab Clin Exp"},{"issue":"3","key":"5947_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1210\/endo-96-3-678","volume":"96","author":"K Mashiter","year":"1975","unstructured":"Mashiter K, Harding PE, Chou M et al (1975) Persistent pancreatic glucagon but not insulin response to arginine in pancreatectomized dogs. Endocrinology 96(3):678\u2013693. https:\/\/doi.org\/10.1210\/endo-96-3-678","journal-title":"Endocrinology"},{"issue":"6","key":"5947_CR18","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.celrep.2017.10.034","volume":"21","author":"NJ Wewer Albrechtsen","year":"2017","unstructured":"Wewer Albrechtsen NJ, Kuhre RE, Hornburg D et al (2017) Circulating glucagon 1\u201361 regulates blood glucose by increasing insulin secretion and hepatic glucose production. Cell Rep 21(6):1452\u20131460. https:\/\/doi.org\/10.1016\/j.celrep.2017.10.034","journal-title":"Cell Rep"},{"issue":"1","key":"5947_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/BF02346248","volume":"7","author":"LG Heding","year":"1971","unstructured":"Heding LG (1971) Radioimmunological determination of pancreatic and gut glucagon in plasma. Diabetologia 7(1):10\u201319. https:\/\/doi.org\/10.1007\/BF02346248","journal-title":"Diabetologia"},{"issue":"9","key":"5947_CR20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1007\/s00125-014-3283-z","volume":"57","author":"NJ Wewer Albrechtsen","year":"2014","unstructured":"Wewer Albrechtsen NJ, Hartmann B, Veedfald S et al (2014) Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels? Diabetologia 57(9):1919\u20131926. https:\/\/doi.org\/10.1007\/s00125-014-3283-z","journal-title":"Diabetologia"},{"issue":"1","key":"5947_CR21","doi-asserted-by":"publisher","first-page":"e001076","DOI":"10.1136\/bmjdrc-2019-001076","volume":"8","author":"K Alexiadou","year":"2020","unstructured":"Alexiadou K, Cuenco J, Howard J et al (2020) Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study. BMJ Open Diabetes Res Care 8(1):e001076. https:\/\/doi.org\/10.1136\/bmjdrc-2019-001076","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"5947_CR22","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2217\/bmm-2016-0090","volume":"10","author":"NJ Wewer Albrechtsen","year":"2016","unstructured":"Wewer Albrechtsen NJ, Kuhre RE, Pedersen J, Knop FK, Holst JJ (2016) The biology of glucagon and the consequences of hyperglucagonemia. Biomark Med 10(11):1141\u20131151. https:\/\/doi.org\/10.2217\/bmm-2016-0090","journal-title":"Biomark Med"},{"issue":"7897","key":"5947_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/s0140-6736(75)92375-2","volume":"1","author":"RH Unger","year":"1975","unstructured":"Unger RH, Orci L (1975) The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1(7897):14\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(75)92375-2","journal-title":"Lancet"},{"issue":"2","key":"5947_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2337\/diabetes.50.2.367","volume":"50","author":"N Flattem","year":"2001","unstructured":"Flattem N, Igawa K, Shiota M, Emshwiller MG, Neal DW, Cherrington AD (2001) Alpha- and beta-cell responses to small changes in plasma glucose in the conscious dog. Diabetes 50(2):367\u2013375. https:\/\/doi.org\/10.2337\/diabetes.50.2.367","journal-title":"Diabetes"},{"issue":"11","key":"5947_CR25","doi-asserted-by":"publisher","first-page":"e156243","DOI":"10.1172\/jci156243","volume":"132","author":"NM Doliba","year":"2022","unstructured":"Doliba NM, Rozo AV, Roman J et al (2022) \u03b1 Cell dysfunction in islets from nondiabetic, glutamic acid decarboxylase autoantibody-positive individuals. J Clin Invest 132(11):e156243. https:\/\/doi.org\/10.1172\/jci156243","journal-title":"J Clin Invest"},{"issue":"11","key":"5947_CR26","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.2337\/db16-0240","volume":"65","author":"K F\u00e6rch","year":"2016","unstructured":"F\u00e6rch K, Vistisen D, Pacini G et al (2016) Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose Regulation. Diabetes 65(11):3473\u20133481. https:\/\/doi.org\/10.2337\/db16-0240","journal-title":"Diabetes"},{"issue":"4","key":"5947_CR27","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s00125-006-0566-z","volume":"50","author":"FK Knop","year":"2007","unstructured":"Knop FK, Vilsb\u00f8ll T, Madsbad S, Holst JJ, Krarup T (2007) Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 50(4):797\u2013805. https:\/\/doi.org\/10.1007\/s00125-006-0566-z","journal-title":"Diabetologia"},{"issue":"2","key":"5947_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/ajcn\/nqy100","volume":"108","author":"M Markova","year":"2018","unstructured":"Markova M, Hornemann S, Sucher S et al (2018) Rate of appearance of amino acids after a meal regulates insulin and glucagon secretion in patients with type 2 diabetes: a randomized clinical trial. Am J Clin Nutr 108(2):279\u2013291. https:\/\/doi.org\/10.1093\/ajcn\/nqy100","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"5947_CR29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1210\/er.2018-00251","volume":"40","author":"NJ Wewer Albrechtsen","year":"2019","unstructured":"Wewer Albrechtsen NJ, Pedersen J, Galsgaard KD et al (2019) The liver-alpha-cell axis and type 2 diabetes. Endocr Rev 40(5):1353\u20131366. https:\/\/doi.org\/10.1210\/er.2018-00251","journal-title":"Endocr Rev"},{"issue":"12","key":"5947_CR30","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.2337\/db11-0979","volume":"60","author":"M Christensen","year":"2011","unstructured":"Christensen M, Vedtofte L, Holst JJ, Vilsboll T, Knop FK (2011) Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60(12):3103\u20133109. https:\/\/doi.org\/10.2337\/db11-0979","journal-title":"Diabetes"},{"key":"5947_CR31","doi-asserted-by":"publisher","first-page":"101071","DOI":"10.1016\/j.molmet.2020.101071","volume":"42","author":"H Chae","year":"2020","unstructured":"Chae H, Augustin R, Gatineau E et al (2020) SGLT2 is not expressed in pancreatic alpha- and beta-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans. Mol Metab 42:101071. https:\/\/doi.org\/10.1016\/j.molmet.2020.101071","journal-title":"Mol Metab"},{"issue":"9","key":"5947_CR32","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s00125-014-3279-8","volume":"57","author":"P Rorsman","year":"2014","unstructured":"Rorsman P, Ramracheya R, Rorsman NJ, Zhang Q (2014) ATP-regulated potassium channels and voltage-gated calcium channels in pancreatic alpha and beta cells: similar functions but reciprocal effects on secretion. Diabetologia 57(9):1749\u20131761. https:\/\/doi.org\/10.1007\/s00125-014-3279-8","journal-title":"Diabetologia"},{"issue":"8","key":"5947_CR33","doi-asserted-by":"publisher","first-page":"bqaa080","DOI":"10.1210\/endocr\/bqaa080","volume":"161","author":"C Dai","year":"2020","unstructured":"Dai C, Walker JT, Shostak A et al (2020) Dapagliflozin does not directly affect human \u03b1 or \u03b2 cells. Endocrinology 161(8):bqaa080. https:\/\/doi.org\/10.1210\/endocr\/bqaa080","journal-title":"Endocrinology"},{"issue":"1","key":"5947_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diabres.2013.11.019","volume":"103","author":"E Gylfe","year":"2014","unstructured":"Gylfe E, Gilon P (2014) Glucose regulation of glucagon secretion. Diabetes Res Clin Pract 103(1):1\u201310. https:\/\/doi.org\/10.1016\/j.diabres.2013.11.019","journal-title":"Diabetes Res Clin Pract"},{"issue":"7","key":"5947_CR35","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41574-018-0020-6","volume":"14","author":"P Rorsman","year":"2018","unstructured":"Rorsman P, Huising MO (2018) The somatostatin-secreting pancreatic delta-cell in health and disease. Nat Rev Endocrinol 14(7):404\u2013414. https:\/\/doi.org\/10.1038\/s41574-018-0020-6","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"5947_CR36","doi-asserted-by":"publisher","first-page":"E207","DOI":"10.1152\/ajpendo.00122.2022","volume":"323","author":"K Maruszczak","year":"2022","unstructured":"Maruszczak K, Rasmussen C, Ceutz FR et al (2022) Arginine-induced glucagon secretion and glucagon-induced enhancement of amino acid catabolism are not influenced by ambient glucose levels in mice. Am J Physiol Endocrinol Metab 323(3):E207\u2013E214. https:\/\/doi.org\/10.1152\/ajpendo.00122.2022","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"5947_CR37","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1172\/JCI107046","volume":"51","author":"DM Rocha","year":"1972","unstructured":"Rocha DM, Faloona GR, Unger RH (1972) Glucagon-stimulating activity of 20 amino acids in dogs. J Clin Invest 51(9):2346\u20132351. https:\/\/doi.org\/10.1172\/JCI107046","journal-title":"J Clin Invest"},{"issue":"11","key":"5947_CR38","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1016\/j.celrep.2018.05.035","volume":"23","author":"LJB Briant","year":"2018","unstructured":"Briant LJB, Dodd MS, Chibalina MV et al (2018) CPT1a-dependent long-chain fatty acid oxidation contributes to maintaining glucagon secretion from pancreatic islets. Cell Rep 23(11):3300\u20133311. https:\/\/doi.org\/10.1016\/j.celrep.2018.05.035","journal-title":"Cell Rep"},{"issue":"4","key":"5947_CR39","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2337\/dbi19-0021","volume":"69","author":"ED Dean","year":"2020","unstructured":"Dean ED (2020) A primary role for \u03b1-cells as amino acid sensors. Diabetes 69(4):542\u2013549. https:\/\/doi.org\/10.2337\/dbi19-0021","journal-title":"Diabetes"},{"issue":"10","key":"5947_CR40","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1172\/JCI106716","volume":"50","author":"WA Muller","year":"1971","unstructured":"Muller WA, Faloona GR, Unger RH (1971) The effect of alanine on glucagon secretion. J Clin Invest 50(10):2215\u20132218. https:\/\/doi.org\/10.1172\/JCI106716","journal-title":"J Clin Invest"},{"issue":"4","key":"5947_CR41","doi-asserted-by":"publisher","first-page":"E660","DOI":"10.1152\/ajpendo.00410.2018","volume":"316","author":"KD Galsgaard","year":"2019","unstructured":"Galsgaard KD, Winther-Sorensen M, Pedersen J et al (2019) Glucose and amino acid metabolism in mice depend mutually on glucagon and insulin receptor signaling. Am J Physiol Endocrinol Metab 316(4):E660\u2013E673. https:\/\/doi.org\/10.1152\/ajpendo.00410.2018","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"5947_CR42","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.2337\/dbi22-0004","volume":"71","author":"MM Richter","year":"2022","unstructured":"Richter MM, Galsgaard KD, Elmelund E et al (2022) The liver-alpha-cell axis in health and in disease. Diabetes 71(9):1852\u20131861. https:\/\/doi.org\/10.2337\/dbi22-0004","journal-title":"Diabetes"},{"issue":"6","key":"5947_CR43","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.2337\/db19-0715","volume":"69","author":"MP Suppli","year":"2020","unstructured":"Suppli MP, Bagger JI, Lund A et al (2020) Glucagon resistance at the level of amino acid turnover in obese subjects with hepatic steatosis. Diabetes 69(6):1090\u20131099. https:\/\/doi.org\/10.2337\/db19-0715","journal-title":"Diabetes"},{"issue":"2","key":"5947_CR44","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41580-020-00317-7","volume":"22","author":"JE Campbell","year":"2021","unstructured":"Campbell JE, Newgard CB (2021) Mechanisms controlling pancreatic islet cell function in insulin secretion. Nat Rev Mol Cell Biol 22(2):142\u2013158. https:\/\/doi.org\/10.1038\/s41580-020-00317-7","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"5947_CR45","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.celrep.2018.10.018","volume":"25","author":"B Svendsen","year":"2018","unstructured":"Svendsen B, Larsen O, Gabe MBN et al (2018) Insulin secretion depends on intra-islet glucagon signaling. Cell Rep 25(5):1127\u20131134. https:\/\/doi.org\/10.1016\/j.celrep.2018.10.018. (e1122)","journal-title":"Cell Rep"},{"issue":"1","key":"5947_CR46","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1210\/endo.141.1.7263","volume":"141","author":"MZ Strowski","year":"2000","unstructured":"Strowski MZ, Parmar RM, Blake AD, Schaeffer JM (2000) Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology 141(1):111\u2013117. https:\/\/doi.org\/10.1210\/endo.141.1.7263","journal-title":"Endocrinology"},{"issue":"3\u20134","key":"5947_CR47","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ceca.2011.11.006","volume":"51","author":"P Rorsman","year":"2012","unstructured":"Rorsman P, Braun M, Zhang Q (2012) Regulation of calcium in pancreatic alpha- and beta-cells in health and disease. Cell calcium 51(3\u20134):300\u2013308. https:\/\/doi.org\/10.1016\/j.ceca.2011.11.006","journal-title":"Cell calcium"},{"issue":"5","key":"5947_CR48","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.jmb.2020.01.004","volume":"432","author":"P Gilon","year":"2020","unstructured":"Gilon P (2020) The role of alpha-cells in islet function and glucose homeostasis in health and type 2 diabetes. J Mol Biol 432(5):1367\u20131394. https:\/\/doi.org\/10.1016\/j.jmb.2020.01.004","journal-title":"J Mol Biol"},{"issue":"3","key":"5947_CR49","doi-asserted-by":"publisher","first-page":"e13464","DOI":"10.1111\/apha.13464","volume":"229","author":"SFS Xu","year":"2020","unstructured":"Xu SFS, Andersen DB, Izarzugaza JMG, Kuhre RE, Holst JJ (2020) In the rat pancreas, somatostatin tonically inhibits glucagon secretion and is required for glucose-induced inhibition of glucagon secretion. Acta Physiol 229(3):e13464. https:\/\/doi.org\/10.1111\/apha.13464","journal-title":"Acta Physiol"},{"issue":"1","key":"5947_CR50","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41467-018-08193-8","volume":"10","author":"E Vergari","year":"2019","unstructured":"Vergari E, Knudsen JG, Ramracheya R et al (2019) Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion. Nat Commun 10(1):139. https:\/\/doi.org\/10.1038\/s41467-018-08193-8","journal-title":"Nat Commun"},{"key":"5947_CR51","doi-asserted-by":"publisher","first-page":"170683","DOI":"10.1016\/j.peptides.2021.170683","volume":"148","author":"DB Andersen","year":"2022","unstructured":"Andersen DB, Holst JJ (2022) Peptides in the regulation of glucagon secretion. Peptides 148:170683. https:\/\/doi.org\/10.1016\/j.peptides.2021.170683","journal-title":"Peptides"},{"issue":"10","key":"5947_CR52","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1007\/s00125-016-4033-1","volume":"59","author":"AE Adriaenssens","year":"2016","unstructured":"Adriaenssens AE, Svendsen B, Lam BY et al (2016) Transcriptomic profiling of pancreatic alpha, beta and delta cell populations identifies delta cells as a principal target for ghrelin in mouse islets. Diabetologia 59(10):2156\u20132165. https:\/\/doi.org\/10.1007\/s00125-016-4033-1","journal-title":"Diabetologia"},{"issue":"1","key":"5947_CR53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0165-1838(86)90045-7","volume":"17","author":"JJ Holst","year":"1986","unstructured":"Holst JJ, Schwartz TW, Knuhtsen S, Jensen SL, Nielsen OV (1986) Autonomic nervous control of the endocrine secretion from the isolated, perfused pig pancreas. J Auton Nerv Syst 17(1):71\u201384. https:\/\/doi.org\/10.1016\/0165-1838(86)90045-7","journal-title":"J Auton Nerv Syst"},{"issue":"252\u201369","key":"5947_CR54","first-page":"252","volume":"303","author":"JJ Holst","year":"1990","unstructured":"Holst JJ (1990) Peptidergic mechanisms in the pancreas. Arch Int Pharmacodyn Ther 303(252\u201369):252\u2013269","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"7","key":"5947_CR55","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/dom.12668","volume":"18","author":"JB Harp","year":"2016","unstructured":"Harp JB, Yancopoulos GD, Gromada J (2016) Glucagon orchestrates stress-induced hyperglycaemia. Diabetes Obes Metab 18(7):648\u2013653. https:\/\/doi.org\/10.1111\/dom.12668","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"5947_CR56","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1748-1716.1978.tb06092.x","volume":"102","author":"H Galbo","year":"1978","unstructured":"Galbo H, Richter EA, Christensen NJ, Holst JJ (1978) Sympathetic control of metabolic and hormonal responses to exercise in rats. Acta Physiol Scand 102(4):441\u2013449. https:\/\/doi.org\/10.1111\/j.1748-1716.1978.tb06092.x","journal-title":"Acta Physiol Scand"},{"issue":"3","key":"5947_CR57","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2337\/diab.24.3.295","volume":"24","author":"JP Palmer","year":"1975","unstructured":"Palmer JP, Ensinck JW (1975) Stimulation of glucagon secretion by ethanol-induced hypoglycemia in man. Diabetes 24(3):295\u2013300. https:\/\/doi.org\/10.2337\/diab.24.3.295","journal-title":"Diabetes"},{"issue":"10","key":"5947_CR58","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.2337\/dc17-0792","volume":"40","author":"L Mumme","year":"2017","unstructured":"Mumme L, Breuer TGK, Rohrer S et al (2017) Defects in alpha-cell function in patients with diabetes due to chronic pancreatitis compared with patients with type 2 diabetes and healthy individuals. Diabetes Care 40(10):1314\u20131322. https:\/\/doi.org\/10.2337\/dc17-0792","journal-title":"Diabetes Care"},{"issue":"11","key":"5947_CR59","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.2337\/diacare.21.11.1960","volume":"21","author":"C Meyer","year":"1998","unstructured":"Meyer C, Grossmann R, Mitrakou A et al (1998) Effects of autonomic neuropathy on counterregulation and awareness of hypoglycemia in type 1 diabetic patients. Diabetes Care 21(11):1960\u20131966. https:\/\/doi.org\/10.2337\/diacare.21.11.1960","journal-title":"Diabetes Care"},{"issue":"1","key":"5947_CR60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2337\/diab.38.1.7","volume":"38","author":"DW Biggers","year":"1989","unstructured":"Biggers DW, Myers SR, Neal D et al (1989) Role of brain in counterregulation of insulin-induced hypoglycemia in dogs. Diabetes 38(1):7\u201316. https:\/\/doi.org\/10.2337\/diab.38.1.7","journal-title":"Diabetes"},{"key":"5947_CR61","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00665.2010","author":"A Lund","year":"2011","unstructured":"Lund A, Vilsboll T, Bagger JI, Holst JJ, Knop FK (2011) The separate and combined impact of the intestinal hormones, GIP, GLP-1 and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab. https:\/\/doi.org\/10.1152\/ajpendo.00665.2010","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"7","key":"5947_CR62","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2337\/db09-1414","volume":"59","author":"KJ Hare","year":"2010","unstructured":"Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ (2010) The glucagonostatic and insulinotropic effects of glucagon-like peptide-1 contribute equally to its glucose-lowering action. Diabetes 59(7):1765\u20131770. https:\/\/doi.org\/10.2337\/db09-1414","journal-title":"Diabetes"},{"issue":"6","key":"5947_CR63","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1089\/met.2017.0015","volume":"15","author":"JJ Holst","year":"2017","unstructured":"Holst JJ, Pedersen J, Wewer Albrechtsen NJ, Knop FK (2017) The gut: a key to the pathogenesis of type 2 diabetes? Metab Syndr Relat Disord 15(6):259\u2013262. https:\/\/doi.org\/10.1089\/met.2017.0015","journal-title":"Metab Syndr Relat Disord"},{"issue":"3","key":"5947_CR64","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","volume":"87","author":"MA Nauck","year":"2002","unstructured":"Nauck MA, Heimesaat MM, Behle K et al (2002) Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87(3):1239\u20131246. https:\/\/doi.org\/10.1210\/jcem.87.3.8355","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"5947_CR65","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2337\/diab.46.5.792","volume":"46","author":"WG Ding","year":"1997","unstructured":"Ding WG, Renstrom E, Rorsman P, Buschard K, Gromada J (1997) Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes 46(5):792\u2013800. https:\/\/doi.org\/10.2337\/diab.46.5.792","journal-title":"Diabetes"},{"issue":"9","key":"5947_CR66","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00125-017-4315-2","volume":"60","author":"A Orgaard","year":"2017","unstructured":"Orgaard A, Holst JJ (2017) The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice. Diabetologia 60(9):1731\u20131739. https:\/\/doi.org\/10.1007\/s00125-017-4315-2","journal-title":"Diabetologia"},{"issue":"4","key":"5947_CR67","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4):1409\u20131439. https:\/\/doi.org\/10.1152\/physrev.00034.2006","journal-title":"Physiol Rev"},{"issue":"4","key":"5947_CR68","doi-asserted-by":"publisher","first-page":"E389","DOI":"10.1152\/ajpendo.00078.2022","volume":"323","author":"A Vasileva","year":"2022","unstructured":"Vasileva A, Marx T, Beaudry JL, Stern JH (2022) Glucagon receptor signaling at white adipose tissue does not regulate lipolysis. Am J Physiol Endocrinol Metab 323(4):E389\u2013E401. https:\/\/doi.org\/10.1152\/ajpendo.00078.2022","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"5947_CR69","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.2337\/db12-1116","volume":"62","author":"KM Habegger","year":"2013","unstructured":"Habegger KM, Stemmer K, Cheng C et al (2013) Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62(5):1453\u20131463. https:\/\/doi.org\/10.2337\/db12-1116","journal-title":"Diabetes"},{"issue":"2","key":"5947_CR70","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1152\/physrev.00025.2016","volume":"97","author":"TD Muller","year":"2017","unstructured":"Muller TD, Finan B, Clemmensen C, DiMarchi RD, Tschop MH (2017) The new biology and pharmacology of glucagon. Physiol Rev 97(2):721\u2013766. https:\/\/doi.org\/10.1152\/physrev.00025.2016","journal-title":"Physiol Rev"},{"issue":"16","key":"5947_CR71","doi-asserted-by":"publisher","first-page":"e129954","DOI":"10.1172\/jci.insight.129954","volume":"4","author":"ME Capozzi","year":"2019","unstructured":"Capozzi ME, Wait JB, Koech J et al (2019) Glucagon lowers glycemia when \u03b2 cells are active. JCI Insight 4(16):e129954. https:\/\/doi.org\/10.1172\/jci.insight.129954","journal-title":"JCI Insight"},{"issue":"2","key":"5947_CR72","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0165-1838(95)00007-K","volume":"54","author":"S Takayama","year":"1995","unstructured":"Takayama S, Nakajima Y, Toma S, Sakamoto T (1995) Increased muscle sympathetic nerve activity after glucagon administration in man. J Auton Nervous Syst 54(2):171\u2013175. https:\/\/doi.org\/10.1016\/0165-1838(95)00007-K","journal-title":"J Auton Nervous Syst"},{"issue":"2","key":"5947_CR73","doi-asserted-by":"publisher","first-page":"E199","DOI":"10.1152\/ajpendo.00304.2022","volume":"324","author":"DS Edgerton","year":"2023","unstructured":"Edgerton DS, Kraft G, Smith M, Farmer B, Williams PE, Cherrington AD (2023) A physiologic increase in brain glucagon action alters the hepatic gluconeogenic glycogenolytic ratio but not glucagon\u2019s overall effect on glucose production. Am J Physiol Endocrinol Metab 324(2):E199\u2013E208. https:\/\/doi.org\/10.1152\/ajpendo.00304.2022","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"5947_CR74","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/s42003-022-04242-7","volume":"5","author":"AB Bomholt","year":"2022","unstructured":"Bomholt AB, Johansen CD, Christensen JB et al (2022) Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression. Commun Biol 5(1):1278. https:\/\/doi.org\/10.1038\/s42003-022-04242-7","journal-title":"Commun Biol"},{"issue":"1","key":"5947_CR75","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/0168-8278(90)90072-Y","volume":"10","author":"H Vilstrup","year":"1990","unstructured":"Vilstrup H, Hansen BA, Almdal TP (1990) Glucagon increases hepatic efficacy for urea synthesis. J Hepatol 10(1):46\u201350. https:\/\/doi.org\/10.1016\/0168-8278(90)90072-Y","journal-title":"J Hepatol"},{"key":"5947_CR76","doi-asserted-by":"publisher","unstructured":"Elmelund E, Galsgaard KD, Johansen CD et al (2022) Opposing effects of chronic glucagon receptor agonism and antagonism on amino acids, hepatic gene expression, and alpha cells. iScience 25(11):105296. https:\/\/doi.org\/10.1016\/j.isci.2022.105296","DOI":"10.1016\/j.isci.2022.105296"},{"issue":"3","key":"5947_CR77","doi-asserted-by":"publisher","first-page":"E263","DOI":"10.1152\/ajpendo.00045.2017","volume":"313","author":"G Kraft","year":"2017","unstructured":"Kraft G, Coate KC, Winnick JJ et al (2017) Glucagon\u2019s effect on liver protein metabolism in vivo. Am J Physiol Endocrinol Metab 313(3):E263-e272. https:\/\/doi.org\/10.1152\/ajpendo.00045.2017","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"5947_CR78","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.celrep.2015.06.034","volume":"12","author":"J Solloway Mark","year":"2015","unstructured":"Solloway Mark J, Madjidi A, Gu C et al (2015) Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of \u03b1-cell mass. Cell Rep 12(3):495\u2013510. https:\/\/doi.org\/10.1016\/j.celrep.2015.06.034","journal-title":"Cell Rep"},{"key":"5947_CR79","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3389\/fphys.2019.00413","volume":"10","author":"KD Galsgaard","year":"2019","unstructured":"Galsgaard KD, Pedersen J, Knop FK, Holst JJ, WewerAlbrechtsen NJ (2019) Glucagon receptor signaling and lipid metabolism. Front Physiol 10:413. https:\/\/doi.org\/10.3389\/fphys.2019.00413","journal-title":"Front Physiol"},{"issue":"4","key":"5947_CR80","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1210\/jcem-16-4-507","volume":"16","author":"R Caren","year":"1956","unstructured":"Caren R, Carbo L (1956) Pancreatic alpha-cell function in relation to cholesterol metabolism. J Clin Endocrinol Metab 16(4):507\u2013516. https:\/\/doi.org\/10.1210\/jcem-16-4-507","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"5947_CR81","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1042\/bj2620425","volume":"262","author":"NF Brown","year":"1989","unstructured":"Brown NF, Salter AM, Fears R, Brindley DN (1989) Glucagon, cyclic AMP and adrenaline stimulate the degradation of low-density lipoprotein by cultured rat hepatocytes. Biochem J 262(2):425\u2013429. https:\/\/doi.org\/10.1042\/bj2620425","journal-title":"Biochem J"},{"key":"5947_CR82","doi-asserted-by":"publisher","first-page":"101639","DOI":"10.1016\/j.molmet.2022.101639","volume":"66","author":"KD Galsgaard","year":"2022","unstructured":"Galsgaard KD, Elmelund E, Johansen CD et al (2022) Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice. Mol Metab 66:101639. https:\/\/doi.org\/10.1016\/j.molmet.2022.101639","journal-title":"Mol Metab"},{"issue":"11","key":"5947_CR83","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.2337\/db22-0313","volume":"71","author":"S Heeb\u00f8ll","year":"2022","unstructured":"Heeb\u00f8ll S, Risikesan J, Ringgaard S et al (2022) Impaired glucagon-mediated suppression of VLDL-triglyceride secretion in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD). Diabetes 71(11):2402\u20132411. https:\/\/doi.org\/10.2337\/db22-0313","journal-title":"Diabetes"},{"issue":"19","key":"5947_CR84","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1056\/NEJM197505082921901","volume":"292","author":"JE Gerich","year":"1975","unstructured":"Gerich JE, Lorenzi M, Bier DM et al (1975) Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. N Engl J Med 292(19):985\u2013989. https:\/\/doi.org\/10.1056\/NEJM197505082921901","journal-title":"N Engl J Med"},{"issue":"2","key":"5947_CR85","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0006-8993(89)91372-3","volume":"504","author":"R Krzeski","year":"1989","unstructured":"Krzeski R, Czyzyk-Krzeska MF, Trzebski A, Millhorn DE (1989) Centrally administered glucagon stimulates sympathetic nerve activity in rat. Brain Res 504(2):297\u2013300. https:\/\/doi.org\/10.1016\/0006-8993(89)91372-3","journal-title":"Brain Res"},{"key":"5947_CR86","unstructured":"Bernard C (1854) Le\u00e7ons de physiologie experimentale appliqu\u00e9s \u00e1 l\u00e1 medecine. J-B Bailli\u00e8re, Paris [in French]"},{"issue":"5041","key":"5947_CR87","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/2101178a0","volume":"210","author":"T Shimazu","year":"1966","unstructured":"Shimazu T, Fukuda A, Ban T (1966) Reciprocal influences of the ventromedial and lateral hypothalamic nuclei on blood glucose level and liver glycogen content. Nature 210(5041):1178\u20131179. https:\/\/doi.org\/10.1038\/2101178a0","journal-title":"Nature"},{"issue":"7","key":"5947_CR88","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.2337\/diabetes.51.7.2056","volume":"51","author":"AA Dunn-Meynell","year":"2002","unstructured":"Dunn-Meynell AA, Routh VH, Kang L, Gaspers L, Levin BE (2002) Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons. Diabetes 51(7):2056\u20132065. https:\/\/doi.org\/10.2337\/diabetes.51.7.2056","journal-title":"Diabetes"},{"issue":"3","key":"5947_CR89","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0361-9230(85)90153-4","volume":"15","author":"WA Banks","year":"1985","unstructured":"Banks WA, Kastin AJ (1985) Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res Bull 15(3):287\u2013292. https:\/\/doi.org\/10.1016\/0361-9230(85)90153-4","journal-title":"Brain Res Bull"},{"issue":"3","key":"5947_CR90","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/0031-9384(84)90160-4","volume":"33","author":"A Inokuchi","year":"1984","unstructured":"Inokuchi A, Oomura Y, Nishimura H (1984) Effect of intracerebroventricularly infused glucagon on feeding behavior. Physiol Behav 33(3):397\u2013400. https:\/\/doi.org\/10.1016\/0031-9384(84)90160-4","journal-title":"Physiol Behav"},{"issue":"2","key":"5947_CR91","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.neulet.2007.02.011","volume":"416","author":"K Honda","year":"2007","unstructured":"Honda K, Kamisoyama H, Saito N, Kurose Y, Sugahara K, Hasegawa S (2007) Central administration of glucagon suppresses food intake in chicks. Neurosci Lett 416(2):198\u2013201. https:\/\/doi.org\/10.1016\/j.neulet.2007.02.011","journal-title":"Neurosci Lett"},{"issue":"12","key":"5947_CR92","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.molmet.2015.09.014","volume":"4","author":"M Quinones","year":"2015","unstructured":"Quinones M, Al-Massadi O, Gallego R et al (2015) Hypothalamic CaMKKbeta mediates glucagon anorectic effect and its diet-induced resistance. Mol Metab 4(12):961\u2013970. https:\/\/doi.org\/10.1016\/j.molmet.2015.09.014","journal-title":"Mol Metab"},{"issue":"7","key":"5947_CR93","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s00125-016-3950-3","volume":"59","author":"MA Abraham","year":"2016","unstructured":"Abraham MA, Lam TKT (2016) Glucagon action in the brain. Diabetologia 59(7):1367\u20131371. https:\/\/doi.org\/10.1007\/s00125-016-3950-3","journal-title":"Diabetologia"},{"key":"5947_CR94","first-page":"372","volume":"90","author":"GC Agarwala","year":"1989","unstructured":"Agarwala GC, Mishra R, Jaiswal G, Bapat V (1989) Effect of centrally administered glucagon on liver glycogen & enzymes in anaesthetised dogs. Indian J Med Res 90:372\u2013378","journal-title":"Indian J Med Res"},{"issue":"6","key":"5947_CR95","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/nm.3115","volume":"19","author":"PI Mighiu","year":"2013","unstructured":"Mighiu PI, Yue JT, Filippi BM et al (2013) Hypothalamic glucagon signaling inhibits hepatic glucose production. Nat Med 19(6):766\u2013772. https:\/\/doi.org\/10.1038\/nm.3115","journal-title":"Nat Med"},{"issue":"3","key":"5947_CR96","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/nejm197007162830301","volume":"283","author":"WA Muller","year":"1970","unstructured":"Muller WA, Faloona GR, Aguilar-Parada E, Unger RH (1970) Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283(3):109\u2013115. https:\/\/doi.org\/10.1056\/nejm197007162830301","journal-title":"N Engl J Med"},{"issue":"7","key":"5947_CR97","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2337\/dc15-1643","volume":"37","author":"CM Kazda","year":"2015","unstructured":"Kazda CM, Garhyan P, Kelly RP et al (2015) A randomized, double-blind, placebo-controlled phase 2 study of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes. Diabetes Care 37(7):1241\u20131249. https:\/\/doi.org\/10.2337\/dc15-1643","journal-title":"Diabetes Care"},{"issue":"4536","key":"5947_CR98","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1126\/science.6278587","volume":"215","author":"DG Johnson","year":"1982","unstructured":"Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D (1982) Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215(4536):1115\u20131116. https:\/\/doi.org\/10.1126\/science.6278587","journal-title":"Science"},{"issue":"314","key":"5947_CR99","doi-asserted-by":"publisher","first-page":"G91","DOI":"10.1152\/ajpgi.00216.2017","volume":"1","author":"NJ Wewer Albrechtsen","year":"2017","unstructured":"Wewer Albrechtsen NJ, Junker AE, Christensen M et al (2017) Hyperglucagonemia correlates with plasma levels of non-branched chained amino acids in patients with liver disease independent of type 2 diabetes. Am J Physiol Gastrointest Liver Physiol 1(314):G91\u2013G96. https:\/\/doi.org\/10.1152\/ajpgi.00216.2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"3","key":"5947_CR100","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00125-017-4535-5","volume":"61","author":"NJ Wewer Albrechtsen","year":"2018","unstructured":"Wewer Albrechtsen NJ, F\u00e6rch K, Jensen TM et al (2018) Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids. Diabetologia 61(3):671\u2013680. https:\/\/doi.org\/10.1007\/s00125-017-4535-5","journal-title":"Diabetologia"},{"issue":"10","key":"5947_CR101","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1038\/s41591-022-02011-x","volume":"28","author":"J Pettus","year":"2022","unstructured":"Pettus J, Boeder SC, Christiansen MP et al (2022) Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med 28(10):2092\u20132099. https:\/\/doi.org\/10.1038\/s41591-022-02011-x","journal-title":"Nat Med"},{"issue":"6","key":"5947_CR102","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/0016-5085(78)90696-0","volume":"74","author":"RS Sherwin","year":"1978","unstructured":"Sherwin RS, Fisher M, Bessoff J et al (1978) Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon. Gastroenterology 74(6):1224\u20131228. https:\/\/doi.org\/10.1016\/0016-5085(78)90696-0","journal-title":"Gastroenterology"},{"issue":"5","key":"5947_CR103","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/joim.12462","volume":"279","author":"AE Junker","year":"2016","unstructured":"Junker AE, Gluud L, Holst JJ, Knop FK, Vilsboll T (2016) Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J Intern Med 279(5):485\u2013493. https:\/\/doi.org\/10.1111\/joim.12462","journal-title":"J Intern Med"},{"issue":"3","key":"5947_CR104","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1172\/jci107624","volume":"53","author":"GL Bilbrey","year":"1974","unstructured":"Bilbrey GL, Faloona GR, White MG, Knochel JP (1974) Hyperglucagonemia of renal failure. J Clin Investig 53(3):841\u2013847. https:\/\/doi.org\/10.1172\/jci107624","journal-title":"J Clin Investig"},{"issue":"1","key":"5947_CR105","doi-asserted-by":"publisher","first-page":"E88","DOI":"10.1152\/ajpendo.1978.235.1.E88","volume":"235","author":"S R\u00f6jdmark","year":"1978","unstructured":"R\u00f6jdmark S, Bloom G, Chou MC, Jaspan JB, Field JB (1978) Hepatic insulin and glucagon extraction after their augmented secretion in dogs. Am J Physiol Endocrinol Metab 235(1):E88. https:\/\/doi.org\/10.1152\/ajpendo.1978.235.1.E88","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"5947_CR106","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2337\/db21-0024","volume":"71","author":"MFG Gr\u00f8ndahl","year":"2021","unstructured":"Gr\u00f8ndahl MFG, Lund AB, Bagger JI et al (2021) Glucagon clearance is preserved in type 2 diabetes. Diabetes 71(1):73\u201382. https:\/\/doi.org\/10.2337\/db21-0024","journal-title":"Diabetes"},{"issue":"11","key":"5947_CR107","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.cmet.2022.09.022","volume":"34","author":"R Sekar","year":"2022","unstructured":"Sekar R, Motzler K, Kwon Y et al (2022) Vps37a regulates hepatic glucose production by controlling glucagon receptor localization to endosomes. Cell Metab 34(11):1824\u20131842. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.022. (e1829)","journal-title":"Cell Metab"},{"issue":"9","key":"5947_CR108","doi-asserted-by":"publisher","first-page":"bvab084","DOI":"10.1210\/jendso\/bvab084","volume":"5","author":"SAS Kjeldsen","year":"2021","unstructured":"Kjeldsen SAS, Hansen LH, Esser N et al (2021) Neprilysin inhibition increases glucagon levels in humans and mice with potential effects on amino acid metabolism. J Endocr Soc 5(9):bvab084. https:\/\/doi.org\/10.1210\/jendso\/bvab084","journal-title":"J Endocr Soc"},{"issue":"11","key":"5947_CR109","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJM197409122911102","volume":"291","author":"JE Gerich","year":"1974","unstructured":"Gerich JE, Lorenzi M, Schneider V et al (1974) Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus. Pathophysiologic and therapeutic implications. N Engl J Med 291(11):544\u2013547. https:\/\/doi.org\/10.1056\/NEJM197409122911102","journal-title":"N Engl J Med"},{"issue":"3","key":"5947_CR110","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1073\/pnas.0237106100","volume":"100","author":"RW Gelling","year":"2003","unstructured":"Gelling RW, Du XQ, Dichmann DS et al (2003) Lower blood glucose, hyperglucagonemia, and pancreatic \u03b1 cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100(3):1438\u20131443. https:\/\/doi.org\/10.1073\/pnas.0237106100","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"5947_CR111","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s00125-006-0481-3","volume":"50","author":"SL Conarello","year":"2007","unstructured":"Conarello SL, Jiang G, Mu J et al (2007) Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50(1):142\u2013150. https:\/\/doi.org\/10.1007\/s00125-006-0481-3","journal-title":"Diabetologia"},{"issue":"10","key":"5947_CR112","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.tem.2020.07.003","volume":"31","author":"T Mezza","year":"2020","unstructured":"Mezza T, Cefalo CMA, Cinti F et al (2020) Endocrine and metabolic insights from pancreatic surgery. Trends Endocrinol Metab 31(10):760\u2013772. https:\/\/doi.org\/10.1016\/j.tem.2020.07.003","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"5947_CR113","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.molmet.2016.05.014","volume":"5","author":"UH Neumann","year":"2016","unstructured":"Neumann UH, Ho JS, Mojibian M, Covey SD, Charron MJ, Kieffer TJ (2016) Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survival. Mol Metab 5(8):731\u2013736. https:\/\/doi.org\/10.1016\/j.molmet.2016.05.014","journal-title":"Mol Metab"},{"issue":"10","key":"5947_CR114","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nchembio.209","volume":"5","author":"JW Day","year":"2009","unstructured":"Day JW, Ottaway N, Patterson JT et al (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5(10):749\u2013757. https:\/\/doi.org\/10.1038\/nchembio.209","journal-title":"Nat Chem Biol"},{"issue":"12","key":"5947_CR115","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/dom.12735","volume":"18","author":"SJ Henderson","year":"2016","unstructured":"Henderson SJ, Konkar A, Hornigold DC et al (2016) Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab 18(12):1176\u20131190. https:\/\/doi.org\/10.1111\/dom.12735","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"5947_CR116","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/dom.13494","volume":"21","author":"J Tillner","year":"2019","unstructured":"Tillner J, Posch MG, Wagner F et al (2019) A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes Metab 21(1):120\u2013128. https:\/\/doi.org\/10.1111\/dom.13494","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"5947_CR117","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD Muller","year":"2022","unstructured":"Muller TD, Bluher M, Tschop MH, DiMarchi RD (2022) Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 21(3):201\u2013223. https:\/\/doi.org\/10.1038\/s41573-021-00337-8","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"5947_CR118","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","volume":"21","author":"B Finan","year":"2015","unstructured":"Finan B, Yang B, Ottaway N et al (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21(1):27\u201336. https:\/\/doi.org\/10.1038\/nm.3761","journal-title":"Nat Med"},{"issue":"9","key":"5947_CR119","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","volume":"34","author":"T Coskun","year":"2022","unstructured":"Coskun T, Urva S, Roell WC et al (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab 34(9):1234\u20131247. https:\/\/doi.org\/10.1016\/j.cmet.2022.07.013. (e1239)","journal-title":"Cell Metab"},{"issue":"10366","key":"5947_CR120","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","volume":"400","author":"S Urva","year":"2022","unstructured":"Urva S, Coskun T, Loh MT et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 400(10366):1869\u20131881. https:\/\/doi.org\/10.1016\/S0140-6736(22)02033-5","journal-title":"Lancet"},{"key":"5947_CR121","doi-asserted-by":"publisher","first-page":"170938","DOI":"10.1016\/j.peptides.2022.170938","volume":"161","author":"SAS Kjeldsen","year":"2023","unstructured":"Kjeldsen SAS, Richter MM, Jensen NJ et al (2023) Development of a glucagon sensitivity test in humans: pilot data and the GLUSENTIC study protocol. Peptides 161:170938. https:\/\/doi.org\/10.1016\/j.peptides.2022.170938","journal-title":"Peptides"},{"issue":"2","key":"5947_CR122","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.molmet.2014.11.005","volume":"4","author":"S Ali","year":"2015","unstructured":"Ali S, Ussher JR, Baggio LL et al (2015) Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol Metab 4(2):132\u2013143. https:\/\/doi.org\/10.1016\/j.molmet.2014.11.005","journal-title":"Mol Metab"},{"issue":"5","key":"5947_CR123","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1210\/jc.2018-00050","volume":"103","author":"KM Petersen","year":"2018","unstructured":"Petersen KM, B\u00f8gevig S, Holst JJ, Knop FK, Christensen MB (2018) Hemodynamic effects of glucagon: a literature review. J Clin Endocrinol Metab 103(5):1804\u20131812. https:\/\/doi.org\/10.1210\/jc.2018-00050","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"5947_CR124","doi-asserted-by":"publisher","first-page":"F469","DOI":"10.1152\/ajprenal.00560.2015","volume":"311","author":"L Bankir","year":"2016","unstructured":"Bankir L, Bouby N, Blondeau B, Crambert G (2016) Glucagon actions on the kidney revisited: possible role in potassium homeostasis. Am J Physiol Renal Physiol 311(2):F469\u2013F486. https:\/\/doi.org\/10.1152\/ajprenal.00560.2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1\u20132","key":"5947_CR125","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0014-2999(82)90572-6","volume":"79","author":"O Watanabe","year":"1982","unstructured":"Watanabe O, Atobe Y, Akagi M, Nishi K (1982) Effects of glucagon on myoelectrical activity of the stomach of conscious and anesthetized dogs. Eur J Pharmacol 79(1\u20132):31\u201341. https:\/\/doi.org\/10.1016\/0014-2999(82)90572-6","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"5947_CR126","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s005350050184","volume":"33","author":"E Mochiki","year":"1998","unstructured":"Mochiki E, Suzuki H, Takenoshita S et al (1998) Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon. J Gastroenterol 33(6):835\u2013841. https:\/\/doi.org\/10.1007\/s005350050184","journal-title":"J Gastroenterol"},{"issue":"2","key":"5947_CR127","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s42255-022-00725-3","volume":"5","author":"PE MacDonald","year":"2023","unstructured":"MacDonald PE, Rorsman P (2023) Metabolic messengers: glucagon. Nat Metab 5(2):186\u2013192. https:\/\/doi.org\/10.1038\/s42255-022-00725-3","journal-title":"Nat Metab"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-05947-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-023-05947-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-05947-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T19:05:21Z","timestamp":1719428721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-023-05947-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,27]]},"references-count":127,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5947"],"URL":"https:\/\/doi.org\/10.1007\/s00125-023-05947-y","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,27]]},"assertion":[{"value":"17 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We acknowledge the many contributors to the glucagon field, including members from our own groups, without whom this review would not have been made possible. This review was based on the international glucagon conference, entitled \u2018A hundred years with glucagon and a hundred more\u2019, held in Copenhagen, Denmark, in November 2022. Figures were created with BioRender.com.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"The review is supported by an unrestricted grant from the Novo Nordic Foundation (NNF21OC0072718) to NJWA in relation to hosting the international glucagon conference in Copenhagen, 1\u20132 November 2022, in the celebration of glucagon\u2019s 100 year birthday. Furthermore, work in the authors\u2019 laboratories is supported by several funding agencies: NJWA is supported by a grant from European Foundation for the Study of Diabetes Future Leader Award (NNF21SA0072746) and a grant from Independent Research Fund Denmark, Sapere Aude (1052\u201300003B); EDD is supported by the National Institute of Health (R01DK132669 and R01DK117147); and TDM received funding from the German Research Foundation (DFG TRR296, TRR152, SFB1123 and GRK 2816\/1), the German Center for Diabetes Research (DZD e.V.) and the European Research Council ERC-CoG Trusted no. 101044445.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NJWA has received funding from, and served on scientific advisory panels and\/or speakers\u2019 bureaus for Boehringer Ingelheim, MSD\/MERCK, Novo Nordisk and Mercodia. JJH has served on scientific advisory panels and received speaker fees for Novo Nordisk. ADC\u2019s external relationships include consulting, research advisory boards and research contract: Abvance; Adipo-Pharma; Cellular Longevity, Inc. dba Loyal; Diakard\/Diabetica; Fractyl Laboratories, Inc; Novo Nordisk, Inc; Sekki Bio; Senda Biosciences, Inc; Sensulin Labs, LLC; Thetis Pharmaceuticals, LLC; vTv Therapeutics. BF is employed at Novo Nordisk. LLG has received funding, consultant fees from and\/or served on scientific advisory panels for Novo Nordisk, Gilead, Becton Dickinson, Sobi, Pfizer and AstraZeneca. JEC receives research funding from Novo Nordisk and Eli Lilly. SRB and TM-MT are shareholders in Zihipp, Ltd. FKK has served on scientific advisory panels and\/or been part of speaker\u2019s bureaus for, served as a consultant to and\/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, Lupin, MedImmune, MSD\/Merck, Mundipharma, Norgine, Novo Nordisk, Pharmacosmos, Sanofi, ShouTi, Zealand Pharma and Zucara; and is a minority shareholder in Antag Therapeutics and co-owner of the weight loss clinic Medicinsk V\u00e6gttabsbehandling ApS. TDM has received funding from Novo Nordisk. The remaining author (DD) declares that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"NJWA, JJH and TDM drafted the first version of the review. ADC, BF, LLG, EDD, JEC, SRB, TM-MT and FKK revised the review for important intellectual content. NJWA drafted figures. All authors approved the version to be published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}